Novel Agents in Breast Cancer and Monoclonal Antibodies
Howard A. “Skip†Burris, III, MD, president, Clinical Operations, chief medical officer and executive director, Drug Development Program, Sarah Cannon, discusses the novel agents in breast cancer and monoclonal antibodies.
Burris mentions the many new classes of therapies discussed for breast cancer, as well as the focus on drugs that will target receptors on the cancer cells and potentially stimulate the immune system.
He also explains the positive results discovered from the treatment of margetuximab in patients.
Howard A. “Skip” Burris, III, MD, president, Clinical Operations, chief medical officer and executive director, Drug Development Program, Sarah Cannon, discusses the novel agents in breast cancer and monoclonal antibodies.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
